In Milan, on May 12, NTC Pharma organised Leader7 Investigators’ Meeting with 90 ophthalmologists representing 57 Italian centers, OPIS Group team and NTC people involved in this clinical research project, one of the widest multicentre clinical studies conducted in Europe in Ophthalmology. NTC is strongly committed in the fight against antibiotic resistance as demonstrated by this study and other initiatives that are building the path of NTC to the Next Level.
NTC is engaged in developing novel therapeutic solutions to satisfy unmet medical needs. On top of large clinical efforts to support its novelties with therapeutic evidences, NTC seeks new innovative solutions to improve a patient friendly and educational approach.
NTC Srl has been named as ‘One to Watch’ in Europe in a list of business excellence published by the European Business Awards. NTC will now have the chance to compete in the Award for Innovation category of the European Business Awards to become a National Winner in Italy. If successful, they will then take part in the grand final in May 2018, where the final 12 European winners will be announced. The European Business Awards is now in its 11th year. Last year it engaged with over 33,000 businesses from 34 countries.